REGENXBIO Secures $100M Milestone from AbbVie as Diabetic Retinopathy Trial Advances
RGNX has more than doubled off its 52-week low of $5.455 on elevated volume (2.8× avg).
Summary
REGENXBIO received a $100 million milestone payment from AbbVie for advancing its diabetic retinopathy gene therapy into a Phase IIb/III trial, significantly boosting its financial position.
Key Events · Product Development and Regulatory · RGNX
-
$100 Million Milestone Payment Received
REGENXBIO announced it has earned a $100 million milestone payment from AbbVie, expected to be received in July 2026.
-
Diabetic Retinopathy Trial Advances to Phase IIb/III
The milestone was triggered by the dosing of the first patient in the Phase IIb/III NAAVIGATE clinical trial of surabgene lomparvovec (sura-vec) in diabetic retinopathy using suprachoroidal delivery.
-
Significant Boost to Financial Runway
This substantial cash infusion, representing nearly 18.5% of the company's market capitalization, provides critical financial stability, especially following recent "going concern doubts" disclosed in the last 10-Q.
-
Upcoming Clinical Data Presentations
The company plans to present two and a half-year data from the ALTITUDE trial (sura-vec for DR) and five-year follow-up data from the Phase I/IIa study (sura-vec for wet AMD) at the ASRS 2026 Annual Meeting in July.
Analysis · RGNX · Life Sciences
REGENXBIO has received a substantial $100 million milestone payment from AbbVie, triggered by the first patient dosed in the Phase IIb/III trial for surabgene lomparvovec in diabetic retinopathy. This significant cash infusion, representing nearly 18.5% of the company's market capitalization, provides critical financial runway and addresses previous "going concern doubts" highlighted in the recent 10-Q. The advancement of this late-stage clinical program also validates the company's gene therapy pipeline and its collaboration with AbbVie.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGNX was trading at $10.98 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $541.8M. The 52-week trading range was $5.46 to $16.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.